DIFFERENTIAL EFFECTS OF LOW AND HIGH MOLECULAR WEIGHT CHITOSAN ADMINISTERED INTRAPERITONEALLY TO MICE INFECTED WITH HELIGMOSOMOIDES POLYGYRUS

• Authors: Klaudia Brodaczewska , Maria Doligalska
• Languages of publication: EN

Abstracts

EN

Aim of the study was to compare the effect of different molecular weight chitosan on activity of
peritoneal cells of mice during immunosupression caused by adult stages of Heligmosomoides
polygyrus. We observed that intraperitoneal injections of chitosan induce cell infiltration, but the
activity of recruited cells differed depending on the type of polysaccharide used. Low molecular
weight chitosan activated cells with inflammatory characteristics, while high molecular weight
polysaccharide reduced cell responsiveness to stimulation. Although IgA titers in the peritoneal
fluid were elevated, chitosan treatments had no effect on the level of infection.

Keywords

EN

chitosan; immune response; parasite

Discipline

• MEDICAL_BIOLOGY: MEDICAL BIOLOGY

• Publisher: Sieć Badawcza Łukasiewicz - Polskie Towarzystwo Chitynowe
• Journal: Progress on Chemistry and Application of Chitin and its Derivatives
• Year: 2013
• Volume: 18
• Issue: 18
• Pages: 77-83

Contributors

author

Klaudia Brodaczewska

• Faculty of Biology, University of Warsaw

author

Maria Doligalska

• Faculty of Biology, University of Warsaw

References

• 1. Sinha VR, Singla AK, Wadhawan S, kaushik R, Kumria R, Bansal K, Dhawan S; (2004) Chitosan microspheres as a potential carrier for drugs. Int J Pharm. 274(1–2):1–33.
• 2. Senel S, McClure SJ; (2004) Potential applications of chitosan in veterinary medicine. Advanced Drug Delivery Review 56;1467–1480
• 3. Wang JJ, Zeng ZW, Xiao RZ, Xie T, Zhou GL, Zhan XR, Wang SL; (2011) Recent advances of chitosan nanoparticles as drug carriers. Int J Nanomedicine. 6:765–774.
• 4. Neimert-Andersson T, Hällgren AC, Andersson M, Langebäck J, Zettergren L, Nilsen-Nygaard J, Draget KI, van Hage M, Lindberg A, Gafvelin G, Grönlund H; (2011) Improved immune responses in mice using the novel chitosan adjuvant ViscoGel, with a Haemophilus influenzae type b glycoconjugate vaccine. Vaccine. Nov 8;29(48):8965-73.
• 5. Tozaki H, Odoriba T, Okada N, Fujita T, Terabe A, Suzuki T, Okabe S, Muranishi S, Yamamoto A; (2002) Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. J Control Release. 82(1):51-61.
• 6. Garcia-Fuentes M, Alonso MJ; (2012) Chitosan-based drug nanocarriers: where do we stand? J Control Release. Jul 20;161(2):496-504.
• 7. Qin C, Gao J, Wang L, Zeng L, Liu Y; (2006) Safety evaluation of short-term exposure to chitooligomers from enzymic preparation. Food Chem Toxicol 44: 855–861
• 8. Hirano S; (1996) Chitin biotechnology applications. Biotechnol Annu Rev 2: 237–258
• 9 . Oliveira MI, Santos SG, Oliveira MJ, Torres AL, Barbosa MA; (2012) Chitosan drives anti-inflammatory macrophage polarisation and pro-inflammatory dendritic cell stimulation. European Cells and Materials Vol. 24 2012 (pages 136-153
• 10 . Illum L, Jabbal-Gill I, Hinchcliffe M, Fisher AN, Davis SS; (2001) Chitosan as a novel nasal delivery system for vaccines. Adv Drug Deliv Rev. Sep 23;51(1-3):81-96.
• 11. Debache K, Kropf C, Schütz CA, Harwood LJ, Käuper P, Monney T, Rossi N, Laue C, McCullough KC, Hemphill A; (2011) Vaccination of mice with chitosan nanogel-associated recombinant NcPDI against challenge infection with Neospora caninum tachyzoites. Parasite Immunol. Feb;33(2):81-94.
• 12. Koppolu B, Zaharoff DA; (2013) The effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cells. Biomaterials. Mar;34(9):2359-69.
• 13. Huang Z, Dong L, Chen J, Gao F, Zhang Z, Chen J, Zhang J; (2012) Low-molecular weight chitosan/vascular endothelial growth factor short hairpin RNA for the treatment of hepatocellular carcinoma. Life Sci. Dec 10;91(23-24):1207-15.
• 14. Maizels RM, Hewitson JP, Murray J, Harcus YM, Dayer B, Filbey KJ, Grainger JR, McSorley HJ, Reynolds LA, Smith KA; (2012) Immune modulation and modulators in Heligmosomoides polygyrus infection. Exp Parasitol. Sep;132(1):76-89.
• 15. Ghosn EE, Cassado AA, Govoni GR, Fukuhara T, Yang Y, Monack DM, Bortoluci KR, Almeida SR, Herzenberg LA, Herzenberg LA; (2010) Two physically, functionally, and developmentally distinct peritoneal macrophage subsets. Proc Natl Acad Sci U S A. Feb 9;107(6):2568-73.
• 16. Ben-Smith A, Wahid FN, Lammas DA, Behnke JM; (1999) The relationship between circulating and intestinal Heligmosomoides polygyrus-specific IgG1 and IgA and resistance to primary infection. Parasite Immunol. 21 (8):383-395
• 17. Kobayashi T, Fukushima K, Sannan T, Saito N, Takiguchi Y, Sato Y, Hasegawa H, Ishikawa K; (2013). Evaluation of the Effectiveness and Safety of Chitosan Derivatives as Adjuvants for Intranasal Vaccines. Viral Immunol. 26(2):133-42.
• 18. Zaharoff DA, Rogers CJ, Hance KW, Schlom J, Greiner JW; (2007) Chitosan solution enhances both humoral and cell-mediated immune responses to subcutaneous vaccination. Vaccine. 25(11): 2085–2094
• 19. Weiner HL; (2001) Oral tolerance: immune mechanisms and the generation of Th3-type TGF-beta-secreting regulatory cells. Microbes and Infection 3(11): 947–954

• Document Type: article